Evaluation of Xpert® MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda
Achilles Katamba, View ORCID ProfileWilly Ssengooba, James Sserubiri, Derrick Semugenze, Kasule George William, Nyombi Abdunoor, Raymond Byaruhanga, Stavia Turyahabwe, Moses L Joloba
doi: https://doi.org/10.1101/2023.04.03.23288099
Achilles Katamba
1Makerere University, Department of Medicine, school of Medicine, Clinical Epidemiology and Biostatistics Unit, Uganda Implementation Research Consortium, Kampala, Uganda
Willy Ssengooba
2Makerere University, Department of Medical Microbiology
3Makerere University Lung Institute
4Makerere University, Biomedical Research Center
James Sserubiri
2Makerere University, Department of Medical Microbiology
4Makerere University, Biomedical Research Center
Derrick Semugenze
2Makerere University, Department of Medical Microbiology
4Makerere University, Biomedical Research Center
Kasule George William
5Ministry of Health, National Tuberculosis and Leprosy Programme
Nyombi Abdunoor
5Ministry of Health, National Tuberculosis and Leprosy Programme
Raymond Byaruhanga
5Ministry of Health, National Tuberculosis and Leprosy Programme
Stavia Turyahabwe
5Ministry of Health, National Tuberculosis and Leprosy Programme
Moses L Joloba
2Makerere University, Department of Medical Microbiology
4Makerere University, Biomedical Research Center
5Ministry of Health, National Tuberculosis and Leprosy Programme
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
Posted April 05, 2023.
Evaluation of Xpert® MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda
Achilles Katamba, Willy Ssengooba, James Sserubiri, Derrick Semugenze, Kasule George William, Nyombi Abdunoor, Raymond Byaruhanga, Stavia Turyahabwe, Moses L Joloba
medRxiv 2023.04.03.23288099; doi: https://doi.org/10.1101/2023.04.03.23288099
Evaluation of Xpert® MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda
Achilles Katamba, Willy Ssengooba, James Sserubiri, Derrick Semugenze, Kasule George William, Nyombi Abdunoor, Raymond Byaruhanga, Stavia Turyahabwe, Moses L Joloba
medRxiv 2023.04.03.23288099; doi: https://doi.org/10.1101/2023.04.03.23288099
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (710)
- Anesthesia (201)
- Cardiovascular Medicine (2952)
- Dermatology (250)
- Emergency Medicine (440)
- Epidemiology (12757)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4593)
- Geriatric Medicine (420)
- Health Economics (729)
- Health Informatics (2923)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (925)
- Medical Education (427)
- Medical Ethics (116)
- Nephrology (469)
- Neurology (4366)
- Nursing (236)
- Nutrition (640)
- Oncology (2274)
- Ophthalmology (647)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1197)
- Primary Care Research (498)
- Public and Global Health (6949)
- Radiology and Imaging (1531)
- Respiratory Medicine (915)
- Rheumatology (438)
- Sports Medicine (385)
- Surgery (489)
- Toxicology (60)
- Transplantation (212)
- Urology (181)